The European Medicines Agency (EMA) supports the application of Quality by Design (QbD) to optimize pharmaceutical manufacturing. This approach ensures the quality of pharmaceuticals through statistical and analytical methods as well as risk management. It involves identifying and controlling sources of variability to ensure that medications meet predefined characteristics right from the start. The concept utilizes multivariate analyses and modern tools to better understand critical attributes and production parameters, enabling continuous improvements.